Source:http://linkedlifedata.com/resource/pubmed/id/18759760
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2008-11-6
|
| pubmed:abstractText |
Gemtuzumab ozogamicin (GO) monotherapy is reported to yield a 20-30% response rate in advanced acute myeloid leukaemia (AML). This study examined the efficacy and tolerability of GO combined with cytarabine (GOCYT) in children with refractory/relapsed CD33(+) AML. Seventeen children received GO 3 mg/m(2) on days 1, 4 and 7 plus cytarabine 100 mg/m(2)/d for 7 d on a compassionate-use basis. Seven patients then received GO-based consolidation. At the outset of GOCYT, two patients were refractory; eight patients were in refractory first relapse; six patients had relapsed after stem cell transplantation (SCT); and one patient [del(5q) therapy-related AML (t-AML)] had not yet been treated. Mean follow-up was 17 months (8-33 months). Ten responses were obtained after GOCYT induction, including complete remission (CR) or CR without complete recovery of platelets (CRp) in six patients (35%). The responses improved in three children who received GOCYT consolidation, increasing the CR + CRp rate to 53%. SCT was subsequently performed in eight responders. Grade 3-4 adverse events consisted of haematological disorders (n = 17, 100%) and documented infections (n = 5, 29%). No cases of sinusoidal obstructive syndrome occurred. Three patients were alive at the cut-off date for this analysis, all of whom had responded to GOCYT. GOCYT combination therapy yielded a high response rate (53%) and showed acceptable toxicity in heavily pretreated children with refractory/relapsed AML. These results warrant a larger prospective study.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Aminoglycosides,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/gemtuzumab
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1365-2141
|
| pubmed:author |
pubmed-author:BaruchelAndréA,
pubmed-author:BertrandYvesY,
pubmed-author:BoutardPatrickP,
pubmed-author:BrethonBenoitB,
pubmed-author:BrunoBénédicteB,
pubmed-author:ChevretSylvieS,
pubmed-author:DalleJean-HuguesJH,
pubmed-author:JéromeCécileC,
pubmed-author:LeblancThierryT,
pubmed-author:NelkenBrigitteB,
pubmed-author:OudotCarolineC,
pubmed-author:YakoubenKarimaK,
pubmed-author:de LumleyLionelL
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
143
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
541-7
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:18759760-Adolescent,
pubmed-meshheading:18759760-Aminoglycosides,
pubmed-meshheading:18759760-Antibodies, Monoclonal,
pubmed-meshheading:18759760-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18759760-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18759760-Child,
pubmed-meshheading:18759760-Child, Preschool,
pubmed-meshheading:18759760-Cytarabine,
pubmed-meshheading:18759760-Drug Administration Schedule,
pubmed-meshheading:18759760-Drug Evaluation,
pubmed-meshheading:18759760-Epidemiologic Methods,
pubmed-meshheading:18759760-Female,
pubmed-meshheading:18759760-Humans,
pubmed-meshheading:18759760-Infant,
pubmed-meshheading:18759760-Leukemia, Myeloid, Acute,
pubmed-meshheading:18759760-Male,
pubmed-meshheading:18759760-Recurrence,
pubmed-meshheading:18759760-Treatment Outcome
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia.
|
| pubmed:affiliation |
Hématologie Pédiatrique, Hôpital Saint-Louis, APHP, Paris, France. benoit.brethon@sls.aphp.fr
|
| pubmed:publicationType |
Journal Article,
Multicenter Study
|